Calamos Advisors LLC Takes $886,000 Position in Augmedix, Inc. (NASDAQ:AUGX)

Calamos Advisors LLC purchased a new position in shares of Augmedix, Inc. (NASDAQ:AUGX) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 151,494 shares of the company’s stock, valued at approximately $886,000.

Other hedge funds also recently added to or reduced their stakes in the company. Vontobel Holding Ltd. lifted its stake in Augmedix by 9.0% in the fourth quarter. Vontobel Holding Ltd. now owns 188,815 shares of the company’s stock worth $1,105,000 after purchasing an additional 15,606 shares during the last quarter. Perkins Capital Management Inc. grew its position in Augmedix by 5.3% in the 4th quarter. Perkins Capital Management Inc. now owns 1,464,568 shares of the company’s stock valued at $8,568,000 after acquiring an additional 73,475 shares during the last quarter. Vanguard Group Inc. increased its stake in Augmedix by 4.8% in the third quarter. Vanguard Group Inc. now owns 1,038,596 shares of the company’s stock worth $5,349,000 after purchasing an additional 47,252 shares during the period. Citigroup Inc. purchased a new stake in shares of Augmedix during the third quarter valued at $241,000. Finally, Walleye Capital LLC increased its stake in Augmedix by 28.9% in the 3rd quarter. Walleye Capital LLC now owns 231,870 shares of the company’s stock worth $1,194,000 after buying an additional 51,975 shares during the period. 87.11% of the stock is currently owned by institutional investors.

Augmedix Trading Down 0.7 %

NASDAQ AUGX opened at $2.99 on Monday. The company’s 50-day simple moving average is $4.02 and its two-hundred day simple moving average is $4.76. Augmedix, Inc. has a one year low of $2.62 and a one year high of $6.25. The company has a market capitalization of $145.73 million, a price-to-earnings ratio of -6.64 and a beta of -0.16. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.41 and a current ratio of 2.41.

Augmedix (NASDAQ:AUGX) last issued its quarterly earnings data on Monday, March 18th. The company reported ($0.09) EPS for the quarter. Augmedix had a negative return on equity of 308.50% and a negative net margin of 42.74%. The business had revenue of $12.68 million during the quarter, compared to the consensus estimate of $12.30 million. Equities analysts forecast that Augmedix, Inc. will post -0.51 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Ian Shakil sold 24,778 shares of the stock in a transaction on Thursday, April 11th. The stock was sold at an average price of $3.93, for a total transaction of $97,377.54. Following the completion of the sale, the insider now owns 3,000 shares in the company, valued at approximately $11,790. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold 251,323 shares of company stock worth $1,005,527 in the last three months. 10.97% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

AUGX has been the topic of a number of research analyst reports. Maxim Group dropped their target price on shares of Augmedix from $6.50 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, March 19th. B. Riley started coverage on Augmedix in a research note on Wednesday, April 3rd. They issued a “buy” rating and a $5.50 price objective on the stock. Finally, Evercore ISI upgraded Augmedix from an “in-line” rating to an “outperform” rating and raised their price objective for the stock from $4.50 to $5.00 in a report on Tuesday, April 9th.

Augmedix Company Profile

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.